VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2020 | Sorafenib vs placebo in treatment-naïve FLT3-ITD AML

Andrew Wei, MBBS, PhD, Alfred Hospital and Monash University, Melbourne, Australia, discusses the results of a Phase II study (ALLG AML M16) aiming to evaluate the efficacy a combined sorafenib and chemotherapy treatment in previously untreated FLT3-ITD acute myeloid leukemia (AML) patients. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter